IVAC TO ACQUIRE SIEMENS INFUSION SYSTEMS' MINIMED INFUSION PUMP line and related disposables under a letter of intent between the San Diego-based Lilly subsidiary and SIS parent Siemens Medical Systems. The proposed agreement, which was announced in a joint May 25 press release, includes related inventory and manufacturing equipment. The deal "is subject to the negotiation and execution of a definitive agreement and to applicable government approval"; terms were not disclosed. The acquisition of the line of MiniMed three-channel pumps will fill out IVAC's infusion pump offerings, which currently include only single-channel devices. IVAC also markets blood pressure monitors, syringe pumps and vital sign measurement devices. The three-channel MiniMed is a "compact and lightweight" pump able to infuse three different fluids into a patient at different rates at one time. The computer-based device, which is used in operating rooms and critical care settings, is currently manufactured at SIS' Sylmar, California facility. After completion of the deal, IVAC plans to move manufacturing to its facility in San Diego. Commenting on the acquisition, IVAC President and CEO William Hawkins said: "SIS' products will provide a quality addition to our product line and bring better service to our valued customers." The press release states that "significant and growing sales confirm that hospitals have responded overwhelmingly to the features and benefits flowing from this new generation technology." The agreement does not include any SIS real estate or production facilities, although IVAC says it will be offering employment to an as yet undetermined number of the approximately 250 SIS employees. The infusion pump line and related disposables covered by the deal, including IV lines and needles, comprise the entirety of SIS' current business.
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.
European venture capital firm Sofinnova Partners’ portfolio companies BioCorteX, Bioptimus, Cure51 and Latent Labs will benefit from the investor’s new partnership with tech giant NVIDIA.
Preparations for the reauthorization of the Medical Device User Fee Amendments for 2028-2032 are underway, with the US FDA announcing a public meeting for 4 August. After negotiations with industry and other stakeholders, a draft agreement is due to Congress by 15 January 2025.
